Thomas McEachin
Known title: DirectorCIK: 0001659781
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
FRT Acquires The Summit For $508M Amid Analyst Downgrades. Federal Realty Investment Trust acquired The Summit in Alabama for $508 million, expanding its retail portfolio. This move coincides with Truist Securities lowering its price target to $116 and Barclays cutting its target to $118, both maintaining neutral stances. The stock is currently trading near key support levels, reflecting a cautious market outlook for the REIT sector.
Transaction History
| MD | ▲ Buy | Grant | 472 | $13K | 8/12/2026 | View on chart |
| FRT | ▼ Sell | Gift | 1,339 | $0 | 6/3/2026 | View on chart |
| FRT | ▼ Sell | Gift | 1,339 | $0 | 6/3/2026 | View on chart |
| MD | ▼ Sell | Gift | 11,427 | $0 | 5/13/2026 | View on chart |
| MD | ▼ Sell | Gift | 11,427 | $0 | 5/13/2026 | View on chart |
| MD | ▲ Buy | Grant | 7,196 | $0 | 5/7/2026 | View on chart |
| FRT | ▲ Buy | Grant | 1,339 | $0 | 1/2/2026 | View on chart |
| FRT | ▼ Sell | Gift | 2,535 | $0 | 9/5/2025 | View on chart |
| FRT | ▼ Sell | Gift | 2,535 | $0 | 9/5/2025 | View on chart |
| MD | ▼ Sell | Gift | 625 | $0 | 8/20/2025 | View on chart |
| MD | ▼ Sell | Gift | 54,021 | $0 | 8/19/2025 | View on chart |
| MD | ▲ Buy | Grant | 11,427 | $0 | 5/8/2025 | View on chart |
| FRT | ▲ Buy | Grant | 1,072 | $0 | 1/2/2025 | View on chart |
| MD | ▲ Buy | Grant | 18,360 | $0 | 5/9/2024 | View on chart |
| FRT | ▲ Buy | Grant | 1,164 | $0 | 1/2/2024 | View on chart |
| MD | ▲ Buy | Grant | 10,965 | $0 | 5/11/2023 | View on chart |
| FRT | ▲ Buy | Grant | 299 | $0 | 1/3/2023 | View on chart |
| MD | ▲ Buy | Grant | 8,480 | $0 | 5/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
MD mentioned in list of stocks with questionable fundamentals
Pediatrix Medical Group (MD) was recently included in a Yahoo Finance article highlighting three unpopular stocks with questionable fundamentals. This mention draws attention to the company's valuation and financial metrics, placing it in a category that some market observers view with caution. The stock currently trades near its 52-week high range, with an average analyst target price of $26.33.
MD mentioned in list of stocks with questionable fundamentals. Pediatrix Medical Group (MD) was recently included in a Yahoo Finance article highlighting three unpopular stocks with questionable fundamentals. This mention draws attention to the company's valuation and financial metrics, placing it in a category that some market observers view with caution. The stock currently trades near its 52-week high range, with an average analyst target price of $26.33.